Pharma news
Europe
German Federal Patent Court invalidates key patent for Xarelto | Bayer faces intensifying generic competition across Europe | Legal team highlights Germany’s crucial role in patent litigation and the importance of stopping early generic entry to protect market exclusivity. 1 August 2025
Americas
Settlement ends expectations of SCOTUS petition | Federal Circuit stipulates patents must explicitly claim the active ingredient of a drug to qualify for Orange Book listing | FTC backs Amneal, saying ‘improper listings’ stifle generic competition. 31 July 2025
Europe
The pharma manufacturer defeats an Italian hemp firm’s EU trademark bid | Claimed name could be confused for its blockbuster drug Xanax | EUIPO found strong market position and product overlap created risk of confusion. 31 July 2025
Americas
Texas pharmacy accused of mass-producing unapproved tirzepatide drugs | Lilly claimed pharmacy falsely marketed copycat versions of Mounjaro and Zepbound as safe and effective | It warned of “conducting a mass testing experiment on consumers without safety controls or informed consent”. 29 July 2025
Americas
Swiss pharma giant files patent infringement lawsuit to stop Teva’s generic Mekinist launch in US | Follows European Patent Office revocation of key patent after Teva proved lack of inventive step. 28 July 2025
Europe
Design and colour combination deemed ‘too common’ in the pharma sector for protection | Court says trademarks must be distinctive across the EU, not just individual countries. 24 July 2025
Americas
$56M awarded to AbbVie unit in Delaware patent fight over Botox treatment | US Botox sales reportedly grew to over $4.4 billion last year, while trade secrets lawsuit against rival continues. 22 July 2025
Americas
Judge said it was unjustified to allow pharma giant’s exclusivity to continue indefinitely | Loss of monopoly over $7.8bn drug set to have marked revenue impact on the company. 22 July 2025
Americas
Delhi High Court has granted an interim injunction against Zydus Lifesciences over the company’s proposed nivolumab product | BMS’s Indian patent covering the monoclonal antibody expires in May 2026. 21 July 2025
Europe
Non-profit alleges that Humira pricing displaced essential healthcare, violated EU competition law and breached human rights | Court notes ‘social significance’ of case—but this can’t translate into ‘legal standing’. 18 July 2025